ID: h-SDA-2026-04-26-gap-pubmed-20260411-090
Hypothesis

Synergistic Timing With Acetylcholinesterase Inhibitors

Scheduled 3mg melatonin 30 minutes after donepezil administration optimizes MT1/AChE-inhibitor cross-talk for amyloid and cholinergic pathway modulation.
🧬 MT1/MT2; AChE; CHRM1 (M1 muscarinic); BACE1🎯 Composite 52%💱 $0.61▲0.5%proposed
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates 9 support 4 oppose
✓ All Quality Gates Passed
Mechanistic 0.55 (15%) Evidence 0.38 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.515 composite

🧪 Overview

Scheduled 3mg melatonin 30 minutes after donepezil administration optimizes MT1/AChE-inhibitor cross-talk for amyloid and cholinergic pathway modulation. However, the synergistic mechanism is not established—cited studies show independent effects not interaction. Pharmacokinetic mismatch: donepezil Tmax is 3-5 hours while melatonin Tmax is 30-60 minutes, making the 30-minute interval rationale unjustified. AChE inhibitors represent 1990s technology as anti-amyloid antibodies become standard. One observational study showed no synergy. Commercial viability limited without novel combination formulation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Donepezil<br/>Administration"]
    B["AChE Inhibition<br/>+ CHRM1 Activation"]
    C["MT1 / MT2<br/>Melatonin Receptor"]
    D["Scheduled Melatonin<br/>30 min Post-Donepezil"]
    E["Synergistic<br/>Cross-talk"]
    F["Amyloid Pathway<br/>Modulation"]
    G["Cholinergic<br/>Protection"]
    A --> B
    D --> C
    B --> E
    C --> E
    E --> F
    E --> G
    style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
    style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix3 supports4 contradicts
Supports
Melatonin and AChE inhibitors show independent neuroprotective effects
Supports
MT1 receptor activation may potentiate muscarinic signaling
Supports
Combination approach addresses both amyloid and cholinergic pathways
Contradicts
MT1/AChE-inhibitor cross-talk mechanism not established in vivo
Contradicts
Donepezil Tmax 3-5h vs melatonin Tmax 30-60min makes 30-min interval pharmacologically irrational
Contradicts
Observational study showed no synergistic cognitive benefit
Contradicts
AChE inhibitor class declining as anti-amyloid antibodies become standard
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MT1

No curated PDB or AlphaFold mapping for MT1 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MT1 →

No DepMap CRISPR Chronos data found for MT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1042
Events (7d)
1
Price History
▲0.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF donepezil 10mg + melatonin 3mg co-administered (30-minute interval) is compared to donepezil alone and melatonin alone in a 24-week trial, THEN the combination group will show statistically signifiCombination therapy will produce a superadditive effect on CSF Aβ42 levels and cognitive function, with interaction term p < 0.05 in mixed-effects model.— no observation —pending0.18
IF patients with Alzheimer's disease receive 3mg melatonin 30 minutes AFTER donepezil (optimized schedule) vs. simultaneous co-administration vs. 4 hours AFTER donepezil (aligned with donepezil Tmax),30-minute post-donepezil melatonin scheduling will produce ≥20% greater reduction in plasma Aβ42 compared to simultaneous or 4-hour delayed administration, demo— no observation —pending0.15
🔮 Falsifiable Predictions (2)
pendingconf 18%
IF donepezil 10mg + melatonin 3mg co-administered (30-minute interval) is compared to donepezil alone and melatonin alone in a 24-week trial, THEN the combination group will show statistically significant synergistic reduction in CSF Aβ42 (not merely additive) and ≥15% improvement inADAS-Cog score b
Predicted outcome: Combination therapy will produce a superadditive effect on CSF Aβ42 levels and cognitive function, with interaction term p < 0.05 in mixed-effects mod
Falsification: Combination effects equal exactly the sum of monotherapy effects (additive) or fall below the sum; interaction term in ANOVA not significant (p ≥ 0.05); or monotherapy-only groups show equal/superior
pendingconf 15%
IF patients with Alzheimer's disease receive 3mg melatonin 30 minutes AFTER donepezil (optimized schedule) vs. simultaneous co-administration vs. 4 hours AFTER donepezil (aligned with donepezil Tmax), THEN plasma Aβ42 concentration will decrease most significantly in the 30-minute interval group com
Predicted outcome: 30-minute post-donepezil melatonin scheduling will produce ≥20% greater reduction in plasma Aβ42 compared to simultaneous or 4-hour delayed administra
Falsification: No significant difference (p > 0.05) in plasma Aβ42 reduction between the 30-minute interval group and simultaneous or 4-hour delayed administration groups; or simultaneous/4-hour groups show numerica
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.